Lucas, Claire M., Scott, Laura J., Carmell, Natasha, Holcroft, Alison K., Hills, Robert K., Burnett, Alan K. and Clark, Richard E. 2018. CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML. Blood Advances 2 (9) , p. 964. 10.1182/bloodadvances.2017013615 |
|
PDF
- Published Version
Download (812kB) | Preview |
Official URL: http://dx.doi.org/10.1182/bloodadvances.2017013615
Abstract
PP2A inhibition occurs in AML by 2 different pathways: CIP2A in normal karyotype patients and SETBP1 in adverse karyotype patients. AKTS473 phosphorylation is a predictor of survival, and diagnostic levels of AKTS473 could be a novel biomarker in AML.
Item Type: | Article |
---|---|
Date Type: | Published Online |
Status: | Published |
Schools: | Medicine |
Publisher: | American Society of Hematology: Blood Advances |
ISSN: | 2473-9529 |
Date of First Compliant Deposit: | 3 August 2018 |
Date of Acceptance: | 16 March 2018 |
Last Modified: | 28 Apr 2020 12:29 |
URI: | http://orca.cf.ac.uk/id/eprint/113883 |
Citation Data
Cited 5 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
![]() |
Edit Item |